Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR have recently announced a significant financing facility agreement worth $600 million. The agreement involves Bausch Receivables Funding LP, a subsidiary of Bausch Health, entering into a non-recourse financing facility with KKR and its credit funds and accounts. This facility will be backed by specific accounts receivables originated by another subsidiary of Bausch Health.
The main objective behind this financing facility is to provide Bausch Health with additional liquidity for general corporate purposes. With an approximate term of five years, the facility aims to enhance the company's financial flexibility.
To facilitate this transaction, Houlihan Lokey, Inc. acted as the financial advisor for Bausch Health while Finacity Corporation provided analytic and execution support as the program administrator.
Bausch Health Companies Inc., a global pharmaceutical company, is dedicated to improving people's lives through its wide range of healthcare products. The company focuses on developing, manufacturing, and marketing various products primarily in areas such as gastroenter